
    
      This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly
      diagnosed triple negative breast cancer comparing changes in biomarkers from a diagnostic
      core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
    
  